



VÄSAMED® APPOINTS CRAIG M. WALKER, MD TO BOARD OF DIRECTORS

MINNEAPOLIS, MN July 29, 2008 — VÄSAMED, INC. (SYMB: VSMD) announced today that Craig M. Walker, M.D., has been elected to the Company's board of directors increasing the number of directors from four to five. Dr. Walker brings over 25 years of medical experience as a practicing cardiologist, clinical investigator and thought leader.

"Dr. Walker will be a great addition to our board. As one of the world's leading experts in the care of patients with peripheral vascular disease as well as the advances in the technology in support of this mission, Dr. Walker will bring tremendous insight and perspective to our organization," said Paulita LaPlante, VÄSAMED, president and chief executive officer.

Dr. Walker is the Founder, President, and Medical Director of the Cardiovascular Institute of the South; Medical Director of the CIS Cardiovascular Fellowship Training Program; Associate Clinical Professor of Medicine Tulane University School of Medicine; and Medical Director of the Cardiac Catheterization Laboratory at Terrebonne General Medical Center.

Dr. Walker has been Principal Investigator in many cardiovascular medical device clinical trials, and has made numerous presentations before the FDA, medical conferences and symposia. He has published over 100 articles, abstracts and books. He is a graduate of the Louisiana State University School of Medicine and is certified by the American Board of Internal Medicine, American College of Physicians, American Board of Internal Medicine – Subspecialty of Cardiovascular Disease, American College of Cardiology, American College of Angiology, American Society for Laser Medicine and Surgery and Diplomat in Interventional Cardiology. Dr. Walker completed his cardiology training at Harvard University's Brigham and Women's Hospital, where he was a research fellow and clinical instructor in cardiology and medicine.

Dr. Walker is intimately involved in advancing innovative technology to improve patients' lives. He is a Board of Director member for Cardiva, CV Therapeutics, IDev and Spectranetics. He is a consultant to Boston Scientific, Cardiva, CV Therapeutics, ev3, FlowMedica, IDev, Possis and Spectranetics, serves on the speaker's bureau for Abbott, AstraZeneca, Boston Scientific, Cardiva, Cordis, CV Therapeutics, FlowMedica, Possis, Spectranetics and Toshiba; and is on the medical/scientific advisory board for Cardiva, Edwards Lifesciences, FlowMedica, Philips, Spectranetics and The Medicine Company.

Commenting on his board appointment, Dr. Walker said, "VÄSAMED is committed to bringing the best noninvasive diagnostic hemodynamic products to the medical community. In practice I have found the SensiLase® System's skin perfusion pressure technology to be a valuable tool to effectively identify patients with peripheral vascular disease, confirm clinical outcomes and assist with patient care decisions."

About VÄSAMED, INC.

VÄSAMED designs, licenses, manufactures and distributes products that are used by physicians in their clinic or procedure lab to determine a patient's hemodynamic and lower extremity arterial health. VÄSAMED products and technology are focused on measuring critical cardiovascular and peripheral information and include SensiLase® Skin Perfusion Pressure and Pulse Volume Recording System to measure capillary perfusion, AcQtrac™ System to monitor heart function, and Tissue Carbon Dioxide Technologies, featuring the MicroStat™ System, to monitor tissue wellness.

Press Release from VÄSAMED, INC.

Contact: Roberta Dircks, CFO
952-944-5857
rdircks@vasamed.com
www.vasamed.com